Clinical Trials · NCT00128531
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- GP-Pharm
- Enrollment
- 120
- Start date
- Sep 2005
- Locations
- 28 sites, 9 countries
- Primary endpoint
- Efficacy: to determine the proportion of patients achieving castration levels of plasma testosterone (defined as <0.5 ng/mL) 4 weeks after the first administration